drugset
drugset / Trial / NCT03594045

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045 ↗

Phase 2 Terminated 5 enrolled Massachusetts General Hospital Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.

Timeline

Start
2018-12-18
Primary completion
2019-10-30
Completion
2019-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 5 mg Oral

Indications

heparin-induced thrombocytopenia